Study suggests the possibility of combination therapy of SORA and FGF21 in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a common human disease and one of the main causes of cancer-related death. The angiogenesis inhibitor Sorafenib (SORA) is commonly used in the treatment of advanced HCC as a first-line drug.
Feb 7, 2024
0
0